Fujifilm Biotechnologies Opens Largest Single-Use CDMO Facility in the UK

Why It Matters

The facility gives biopharma companies faster, flexible access to mid‑scale production in Europe, strengthening supply‑chain resilience and accelerating drug development for high‑need therapies. It also underscores Fujifilm’s strategic push into modular, sustainable biomanufacturing.

Key Takeaways

• £400m investment creates UK's largest single-use CDMO
• 2,000 L and 5,000 L reactors total 19,000 L capacity
• Bioprocess Innovation Centre doubles lab footprint, adds high‑throughput capability
• kojoX modular platform enables rapid cross‑site technology transfer
• Fully electrified building supports Fujifilm sustainability goals

Pulse Analysis

The single‑use bioprocessing wave has reshaped contract development and manufacturing, offering lower capital outlay and faster turnaround compared with stainless‑steel systems. Fujifilm’s £400 million Teesside expansion taps this momentum, delivering the UK’s biggest single‑use CDMO footprint and positioning the region as a hub for mid‑scale antibody production. By bundling 2,000‑liter and 5,000‑liter bioreactors into a 19,000‑liter capacity, the site bridges the gap between early‑stage clinical batches and commercial scale, a niche increasingly demanded by biotech firms seeking agile supply chains.

Central to the launch is the kojoX modular platform, a global initiative that standardizes equipment, data, and processes across Fujifilm’s sites. This harmonization accelerates technology transfer, allowing a product developed in the UK to move seamlessly to the Toyama, Japan facility or vice‑versa, cutting months off development timelines. The fully electrified, renewable‑energy‑focused building aligns with industry‑wide sustainability goals, reducing carbon footprints while maintaining GMP compliance. Together, these elements enhance speed to market and provide partners with a reliable, scalable manufacturing pathway.

Beyond the walls of the new plant, the Bioprocess Innovation Centre creates a collaborative nexus for academia and industry. Partnerships with the Universities of Edinburgh, Manchester and York foster talent pipelines and joint research, reinforcing the UK’s life‑science ecosystem. The centre’s high‑throughput and continuous processing capabilities enable rapid process optimization, crucial for complex therapies such as oncology, neurodegeneration and rare diseases. As demand for flexible, sustainable biomanufacturing grows, Fujifilm’s Teesside site is poised to become a strategic asset for global drug developers.